Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma
Abstract Background Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide every year, and most HCC patients are diagnosed with advanced disease and can only receive systemic treatment. TKIs are the most important components of the systemic treatment of HCC and...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-10-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-022-02542-0 |
| _version_ | 1811328514664693760 |
|---|---|
| author | Xiaoying Gu Su Zhang Xuejiao Yang Tao Guan Zhenyu Hou Manqing Cao Huikai Li Ti Zhang |
| author_facet | Xiaoying Gu Su Zhang Xuejiao Yang Tao Guan Zhenyu Hou Manqing Cao Huikai Li Ti Zhang |
| author_sort | Xiaoying Gu |
| collection | DOAJ |
| description | Abstract Background Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide every year, and most HCC patients are diagnosed with advanced disease and can only receive systemic treatment. TKIs are the most important components of the systemic treatment of HCC and have both good efficacy and adverse events (AEs). Methods This analysis included 207 patients with locally advanced unresectable or metastatic HCC who received oral treatment with apatinib. We analyzed the overall survival (OS) and progression-free survival (PFS) of patients with or without corresponding AEs to evaluate which AEs can predict the efficacy of apatinib. Results Patients with hand-foot syndrome (HFS; p = 0.005), proteinuria (p = 0.006) and diarrhea (p < 0.001) had significantly better OS than those without corresponding AEs, and the appearance of HFS (p = 0.006) and proteinuria (p = 0.004) was associated with longer PFS. Conclusion Among all the AEs induced by apatinib in the treatment of advanced HCC, proteinuria could potentially predict PFS, and diarrhea was a potential predictor of OS. |
| first_indexed | 2024-04-13T15:26:28Z |
| format | Article |
| id | doaj.art-323bfbde9e90432080b00bd8cf30739c |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-04-13T15:26:28Z |
| publishDate | 2022-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-323bfbde9e90432080b00bd8cf30739c2022-12-22T02:41:29ZengBMCBMC Gastroenterology1471-230X2022-10-012211910.1186/s12876-022-02542-0Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinomaXiaoying Gu0Su Zhang1Xuejiao Yang2Tao Guan3Zhenyu Hou4Manqing Cao5Huikai Li6Ti Zhang7Department of Hepatobiliary Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerDepartment of Gynecologic Oncology, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerDepartment of Hepatobiliary Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerDepartment of Hepatobiliary Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerDepartment of Hepatobiliary Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerDepartment of Breast Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerDepartment of Hepatobiliary Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerDepartment of Hepatobiliary Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerAbstract Background Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide every year, and most HCC patients are diagnosed with advanced disease and can only receive systemic treatment. TKIs are the most important components of the systemic treatment of HCC and have both good efficacy and adverse events (AEs). Methods This analysis included 207 patients with locally advanced unresectable or metastatic HCC who received oral treatment with apatinib. We analyzed the overall survival (OS) and progression-free survival (PFS) of patients with or without corresponding AEs to evaluate which AEs can predict the efficacy of apatinib. Results Patients with hand-foot syndrome (HFS; p = 0.005), proteinuria (p = 0.006) and diarrhea (p < 0.001) had significantly better OS than those without corresponding AEs, and the appearance of HFS (p = 0.006) and proteinuria (p = 0.004) was associated with longer PFS. Conclusion Among all the AEs induced by apatinib in the treatment of advanced HCC, proteinuria could potentially predict PFS, and diarrhea was a potential predictor of OS.https://doi.org/10.1186/s12876-022-02542-0ApatinibAnti-angiogenesis therapyAdverse EventsHepatocellular CarcinomaPrognosis |
| spellingShingle | Xiaoying Gu Su Zhang Xuejiao Yang Tao Guan Zhenyu Hou Manqing Cao Huikai Li Ti Zhang Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma BMC Gastroenterology Apatinib Anti-angiogenesis therapy Adverse Events Hepatocellular Carcinoma Prognosis |
| title | Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma |
| title_full | Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma |
| title_fullStr | Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma |
| title_full_unstemmed | Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma |
| title_short | Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma |
| title_sort | drug related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma |
| topic | Apatinib Anti-angiogenesis therapy Adverse Events Hepatocellular Carcinoma Prognosis |
| url | https://doi.org/10.1186/s12876-022-02542-0 |
| work_keys_str_mv | AT xiaoyinggu drugrelatedadverseeventspotentiallypredicttheefficacyofapatinibonadvancedhepatocellularcarcinoma AT suzhang drugrelatedadverseeventspotentiallypredicttheefficacyofapatinibonadvancedhepatocellularcarcinoma AT xuejiaoyang drugrelatedadverseeventspotentiallypredicttheefficacyofapatinibonadvancedhepatocellularcarcinoma AT taoguan drugrelatedadverseeventspotentiallypredicttheefficacyofapatinibonadvancedhepatocellularcarcinoma AT zhenyuhou drugrelatedadverseeventspotentiallypredicttheefficacyofapatinibonadvancedhepatocellularcarcinoma AT manqingcao drugrelatedadverseeventspotentiallypredicttheefficacyofapatinibonadvancedhepatocellularcarcinoma AT huikaili drugrelatedadverseeventspotentiallypredicttheefficacyofapatinibonadvancedhepatocellularcarcinoma AT tizhang drugrelatedadverseeventspotentiallypredicttheefficacyofapatinibonadvancedhepatocellularcarcinoma |